Nghiên cứu qui trình tổng hợp liên tục và tinh chế celecoxib

ĐẠI HỌC QUỐC GIA HÀ NỘI
TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN

TRẦN THỊ YẾN

NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ
CELECOXIB

LUẬN VĂN THẠC SĨ KHOA HỌC


ĐẠI HỌC QUỐC GIA HÀ NỘI
TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN

TRẦN THỊ YẾN

NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ
CELECOXIB

Chuyên nghành: Hóa hữu cơ
Mã số: 60440114

LUẬN VĂN THẠC SĨ KHOA HỌC

Người hướng dẫn khoa học: TS. Ngô Quốc Anh

Hà Nội - 2016


TÀI LIỆU THAM KHẢO
A. Tiếng Việt

1. Đào Văn Phan (2007), Dược lý học, tập 1, Nhà xuất bản Giáo dục, Hà Nội .
2. Mai Tất Tố (2007), Dược lý học, tập 2, Nhà xuất bản Y học, Hà Nội.
3.

(2010), Vidal Việt Nam, Nhà xuất bản CMPMedica Asia Pte Ltd, Tp Hồ Chí
Minh
B. Tiếng Anh

4.

Anumula, et al. (2008), Process for preparation of celecoxib, US patent, US
20080234491A1

5. Beuck M. (1999), "Nonsteroidal antiinflammatory drugs: A new generation
of cyclooxygenase inhibitors", Angew. Chem. Int. Ed., 38, pp. 0631-0633.
6. Coruzzi G., Venturi N., Spaggiari S. (2007), " Gastrointestinal safety of
novel nonsteroidal antiinflammatory drugs: Selective cox-2 inhibitors
and beyond", Acta Biomed, 78, pp. 96-110.
7. Davies N. M., et al. (2000), "Clinical pharmacokinetics and pharmacodynamics
of celecoxib: A selective cyclo-oxygenase-2 inhibitor", Clin Pharmacokinet,
38(3), pp. 225-242.
8. Farooq M., et al. (2008), " Cardiovascular risks of cox inhibition: Current
perspectives", A.S.Expert Opin. Pharmacother, 9, pp. 1311-1319.
9. Ferro, et al. (2004), Polymorphic crystalline forms of celecoxib, United
States Patent, US 20040087640A1(5/2004).


10. Frampton J. E., Keating G. M. (2007), "Celecoxib: A review of its use in the
management of arthritis and acute pain", Drugs, 67(16), pp. 2433-2472.
11. Furniss B. S., et al. (1989), "Vogel's textbook of practical organic

chemistry", Longman Scientific & technical, 5th edition, pp. 959.
12. Gandey A. (2011), "All nonsteroidal anti-inflammatory drugs have
cardiovascular ricks", BMJ.
13. Harris R. E., et al. (2000), "Chemoprevention of breast cancer in rats by
celecoxib, a cyclooxygenase 2 inhibitor", Cancer Res, 60(8), pp. 2101-2103.
14. Jeffery S. C. (2000), "Inhibitors of cyclooxygenase-2", Exp. Opin. Ther.
Patents, 10(7), pp. 1011-1020.
15. Jones R., et al. ( 2008), "Gastrointestinal and cardiovascular risks of
nonsteroidal antiinflammatory drugs", Am. J. Med., 121, pp. 464-474.
16. Kalgutkar A. S. , Lawrence J. M. (1998), "Design of selective inhibitors of
cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents", Current
Opinion in Chemical Biology, 2, pp. 482-490.
17. Letendre, et al. (2007), "Synthesis of diaryl pyrazoles", US patent, US
20070004924A1(1/2007).
18. Li J. J. , et al. (2004), "Anti-inflammatory cyclooxygenase-2 selective
inhibitors: Celecoxib (celebrex) and rofecoxib (vioxx)", Contemporary Drug
Synthesis, pp. 11-19.
19. Loewen P. S. (2002), "Review of the selective cox-2 inhibitors celecoxib and
rofecoxib: Focus on clinical aspects", CJEM, 4(4), pp. 268-275.


20. Lynette M. O. (2006), "Synthesis of celecoxib via 1,3-dipolar cycloaddition",
ScienceDirect, 47(45), pp. 7943-7946.
21. Masferrer J. L., et al. (2000), "Antiangiogenic and antitumor activities of
cyclooxygenase-2 inhibitors", Cancer Res, 60(5), pp. 1306-1311.
22. Micheal B. S. , Jerry March (2001), "March's advanced organic chemistry:
Reactions, mechanisms and structure", Wiley - Interscience, 5th edition, pp.
1556.
23. Moore R. A., et al. (2005), "Tolerability and adverse events in clinical trials of
celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and

meta-analysis of information from company clinical trial reports", Arthritis
Res Ther, 7(3), pp. R644-665.
24. O'Shea, et al. (2001), Synthesis of 4-[(5-substituted phenyl)-3-substituted-lhpyrazol-l-yljbenzenesulfonamide, United States Patent, S006232472B1
(5/2001).
25. Penning T. D., et al. (1997), "Synthesis and biological evaluation of the 1,5diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benze nesulfonamide (sc58635, celecoxib)", J Med Chem, 40(9), pp. 1347-1365.
26. Reddy B. S., et al. (2000), "Chemoprevention of colon cancer by specific
cyclooxygenase-2 inhibitor, celecoxib, administered during different stages
of carcinogenesis", Cancer Res, 60(2), pp. 293-297.
27. Reddy M., et al. (2003), Process for the preparation of 1,5-diarylpyraroles,
World Intellectual Property Organization, WO 03/024400 A2.(3/2003).
28. Sanghi S., et al. (2006), "Cyclooxygenase-2 inhibitors: A painful lesson",
Cardiovasc Hematol Disord Drug Targets, 6(2), pp. 85-100.


29. Silverstein F. E., et al. (2000), "Gastrointestinal toxicity with celecoxib vs
nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid
arthritis: The class study: A randomized controlled trial. Celecoxib long-term
arthritis safety study", JAMA, 284(10), pp. 1247-1255.
30. Simon L. S., et al. (1999), "Anti-inflammatory and upper gastrointestinal
effects of celecoxib in rheumatoid arthritis: A randomized controlled trial",
JAMA, 282(20), pp. 1921-1928.
31. Talley J. J., et al. (2003), Substituted pyrazolyl benzenesulfonamides for the
treatment of inflammation, US patent, 6,586,603,B1(6/2003).
32. Vane J. ( 1994), "Towards a better aspirin. ", Nature, 367, pp. 215-216.
33. Zhuang, et al. (2004), Stable amorphous celecoxib composite and process
therefor, Patent Application Publication, US 20040030151A1(2/2004).
34. Zhi B., Estates H.; Newaz M., PalatineIll.( 1999), U.S. Pat. Nos. 5,910,597.